RxDoctor Payments Data

Jayraj Jhala, MD

Internal Medicine · Alcoa, TNNPI 1215014360

Payments from drug & device makers

$485in general payments, 2019–2025

Across 28 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$109
  • Merck$95
  • AbbVie$86
  • Novo Nordisk$78
  • Corcept Therapeutics$20
  • Sanofi-aventis U.S. LLC$20
  • plus $79 from 5 others

What the payments were for

  • Food & beverage$485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$485 in reported general payments places this provider in the 55th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$175,090
Medicare patients
580
Services billed
2,483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban207$203,189
OzempicSemaglutide124$159,904
MounjaroTirzepatide102$128,102
TrulicityDulaglutide40$57,428
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$49,345
ProliaDenosumab19$32,883
JardianceEmpagliflozin24$29,350
FarxigaDapagliflozin Propanediol19$22,215
MyrbetriqMirabegron24$21,727
XareltoRivaroxaban24$21,497
RybelsusSemaglutide17$19,214
GlyxambiEmpagliflozin/Linagliptin17$18,863
VraylarCariprazine Hcl15$18,428
Breo ElliptaFluticasone/Vilanterol15$14,596
LinzessLinaclotide14$14,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$203,189207 claims
Novo NordiskOzempic, Rybelsus$78$179,118141 claims
AbbVieVraylar, Linzess, Synthroid$86$37,02987 claims
Johnson & JohnsonXarelto$109$21,49724 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$20$17,68536 claims
NovartisEntresto$16$8,20012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Alcoa

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →